Sclerotherapy of Ranula with Intracystic Injection of OK-432.
- Author:
Hyo Seon KIM
1
;
Jong Lyel ROH
Author Information
1. Department of Otolaryngology-Head and Neck Surgery, Cancer Research Institute, Chungnam National University College of Medicine, Daejeon, Korea. happyfam@paran.com
- Publication Type:Original Article
- Keywords:
OK-432;
Sclerotherapy;
Ranula
- MeSH:
Cicatrix;
Follow-Up Studies;
Humans;
Mucus;
Picibanil*;
Ranula*;
Recurrence;
Rupture;
Sclerotherapy*
- From:Korean Journal of Otolaryngology - Head and Neck Surgery
2006;49(10):1003-1007
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND AND OBJECTIVES : Although surgery is the first choice of therapy for ranula, sometimes complete excision is very difficult. Therefore, nonsurgical therapies with less associated morbidity have been required for the treatment of ranula. This study examined the effectiveness of intracystic injection of OK-432 for treatment of ranula. SUBJECTS AND METHOD : Total 32 patients with ranula (24, intraoral type ; 8, plunging type) were treated with OK-432 sclerotherapy. Aspirated mucus of ranula was replaced with an equal volume of OK-432 solution of 0.01 mg/mL. The size of ranula was compared before and after sclerotherapy. RESULTS : Twenty five of 32 patients (78%) showed a complete response after sclerotherapy : higher in plunging ranula (88%) than in intraoral ranula (75%). Rupture of ranula developed in 8 of 25 patients (32%) with intraoral ranula within a few days after injection. Recurrence occurred in 3 patients during follow-up period of median 12 months (range 9-22 months) after last injection. There were no major side effects, scarring, or increased morbidity to surgery of the OK-432 injected lesions. CONCLUSION : The intracystic injection of OK-432 is highly effective as a primary treatment modality of ranula.
